…
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cronos Group Inc is a Canadian cannabis company that develops, cultivates and distributes adult-use and hemp-derived products through owned brands and manufacturing operations. Growth drivers include expansion of legalized markets, product innovation and a strategic investor relationship that may support scale. The company may appeal to investors seeking exposure to the legalized cannabis industry and potential upside from market liberalization.
Major risks include regulatory uncertainty, intense competition and margin pressure, execution and profitability challenges as the business scales, and reliance on partnerships and capital markets.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -17.42M | 36.55M | -73.49M | -134.56M | -397.13M |
| Minority interest | -6.52M | 1.06M | 0.59M | 0.00M | 1.10M |
| Net income | -9.61M | 41.04M | -73.79M | -168.73M | -396.70M |
| Selling general administrative | 70.81M | 76.82M | 58.23M | 86.29M | 106.63M |
| Selling and marketing expenses | - | - | 22.70M | 22.28M | 44.94M |
| Gross profit | 61.70M | 30.45M | 11.88M | 11.97M | -17.53M |
| Reconciled depreciation | 14.23M | 9.34M | 8.11M | 13.12M | 15.40M |
| Ebit | -17.84M | -54.21M | -79.72M | -116.01M | 6.79M |
| Ebitda | -3.36M | -45.37M | -72.28M | -59.19M | 22.19M |
| Depreciation and amortization | 14.48M | 8.84M | 7.44M | 56.83M | 15.40M |
| Operating income | -17.84M | -76.46M | -84.60M | -116.01M | 6.79M |
| Other operating expenses | 166.99M | 193.96M | 171.63M | 207.92M | 271.35M |
| Interest expense | - | - | - | 22.54M | 0.03M |
| Tax provision | -14.19M | -3.44M | -3.23M | 34.17M | -0.43M |
| Interest income | 39.96M | 138.51M | 51.23M | 52.16M | 162.73M |
| Net interest income | 39.96M | 52.02M | 51.23M | 22.54M | 9.07M |
| Extraordinary items | - | 0.00M | -4.11M | 0.00M | -0.50M |
| Income tax expense | -14.44M | -3.44M | -3.23M | 34.17M | -0.43M |
| Total revenue | 149.15M | 117.50M | 87.03M | 91.90M | 74.44M |
| Total operating expenses | 79.54M | 106.91M | 96.48M | 127.98M | 179.38M |
| Cost of revenue | 87.45M | 87.05M | 75.15M | 79.94M | 91.97M |
| Total other income expense net | 0.42M | 113.01M | 11.10M | -18.55M | -403.92M |
| Discontinued operations | - | - | - | - | -0.50M |
| Net income from continuing ops | -2.93M | 40.02M | -70.44M | -168.73M | -396.70M |
| Net income applicable to common shares | - | 41.08M | -73.96M | -168.73M | -396.11M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1194.96M | 1166.31M | 1140.09M | 1213.01M | 1397.74M |
| Intangible assets | 8.87M | 11.13M | 21.08M | 26.70M | 18.08M |
| Other current assets | 8.33M | 6.28M | 5.41M | 7.11M | 8.97M |
| Total liab | 54.08M | 55.33M | 43.96M | 72.05M | 63.46M |
| Total stockholder equity | 1091.91M | 1064.06M | 1099.57M | 1143.88M | 1337.24M |
| Other current liab | 36.14M | 0.04M | 0.10M | 55.62M | 40.44M |
| Common stock | 661.78M | - | 613.73M | 611.32M | 595.50M |
| Capital stock | 662.98M | 669.88M | 613.73M | 611.32M | 595.50M |
| Retained earnings | 446.94M | 457.71M | 416.72M | 490.68M | 659.42M |
| Other liab | - | - | - | 1.38M | 1.99M |
| Good will | 66.36M | 63.45M | 1.06M | 1.03M | 1.10M |
| Other assets | - | - | - | 0.19M | 80.73M |
| Cash | 790.35M | 858.80M | 669.29M | 764.64M | 886.97M |
| Cash and equivalents | - | - | - | 764.64M | 886.97M |
| Total current liabilities | 48.10M | 49.70M | 41.40M | 68.12M | 54.37M |
| Current deferred revenue | - | - | 28.17M | - | - |
| Net debt | -787.68M | - | -666.74M | -760.77M | -877.17M |
| Short term debt | 0.34M | - | 0.99M | 1.33M | 2.71M |
| Short long term debt total | 2.68M | - | 2.55M | 3.88M | 9.81M |
| Other stockholder equity | - | - | 48.45M | 42.68M | 32.47M |
| Property plant equipment | - | - | - | 62.83M | 82.95M |
| Total current assets | 942.37M | 936.11M | 933.31M | 960.16M | 1079.72M |
| Long term investments | 7.66M | 2.81M | 54.74M | 89.75M | 135.16M |
| Net tangible assets | - | - | - | 1116.15M | 1318.07M |
| Short term investments | 39.93M | 0.00M | 192.24M | 113.08M | 117.68M |
| Net receivables | 57.09M | 15.46M | 35.88M | 37.77M | 33.29M |
| Inventory | 46.66M | 33.15M | 30.50M | 37.56M | 32.80M |
| Accounts payable | 11.62M | 16.97M | 12.13M | 11.16M | 11.22M |
| Accumulated other comprehensive income | -16.81M | - | 20.68M | -0.80M | 49.87M |
| Non currrent assets other | - | - | 0.04M | 72.54M | 80.73M |
| Non current assets total | 252.59M | 230.07M | 206.78M | 252.85M | 318.02M |
| Capital lease obligations | 1.51M | 2.02M | 2.55M | 3.88M | 9.81M |
| Long term debt total | - | - | - | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -45.11M | 175.15M | -59.50M | -1.84M | -19.41M |
| Change to liabilities | - | - | - | -0.86M | -2.37M |
| Total cashflows from investing activities | -77.90M | 175.15M | -59.50M | -1.84M | -28.90M |
| Total cash from financing activities | -20.25M | -1.23M | -1.03M | -2.90M | -13.44M |
| Change to operating activities | - | - | - | -2.76M | 1.97M |
| Net income | -9.61M | 40.02M | -74.55M | -168.73M | -397.20M |
| Change in cash | -109.07M | 189.51M | -95.35M | -122.33M | -191.05M |
| Begin period cash flow | 899.42M | 669.29M | 764.64M | 886.97M | 1078.02M |
| End period cash flow | 790.35M | 858.80M | 669.29M | 764.64M | 886.97M |
| Total cash from operating activities | 26.32M | 18.84M | -42.84M | -88.95M | -153.62M |
| Depreciation | 14.48M | 9.34M | 8.11M | 13.12M | 15.40M |
| Other cashflows from investing activities | - | -4.25M | 18.61M | 3.19M | -16.64M |
| Change to inventory | -10.58M | 7.42M | 7.40M | -7.22M | 11.56M |
| Change to account receivables | -26.20M | -2.51M | 9.21M | -2.71M | -13.16M |
| Sale purchase of stock | -9.91M | - | -1.36M | - | 0.02M |
| Other cashflows from financing activities | -10.34M | -1.23M | -1.03M | -2.90M | -13.44M |
| Change to netincome | - | - | - | 46.00M | 229.09M |
| Capital expenditures | 26.17M | 13.15M | 3.42M | 5.03M | 12.26M |
| Change in working capital | -35.02M | -0.31M | -26.47M | 20.66M | -2.00M |
| Stock based compensation | 7.05M | 8.70M | 8.77M | 15.12M | 10.15M |
| Other non cash items | 56.47M | -38.90M | -2.01M | 30.89M | 220.04M |
| Free cash flow | 0.15M | 5.69M | -46.26M | -93.98M | -165.88M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CRON Cronos Group Inc |
0.16 3.36% |
4.92 | - | 32.15 | 9.80 | 0.95 | 1.47 | 1.90 |
| CURA Curaleaf Holdings Inc. |
-0.74 5.20% |
13.49 | - | 138.89 | 2.57 | 3.14 | 2.47 | 13.10 |
| BHC Bausch Health Companies Inc |
0.31 2.72% |
11.72 | 13.98 | 1.35 | 0.28 | 18.74 | 2.12 | 6.84 |
| TLRY Tilray Inc |
0.41 11.02% |
4.13 | - | 1000.00 | 1.28 | 0.53 | 1.08 | -2.30 |
| GUD Knight Therapeutics Inc. |
0.02 0.18% |
11.28 | - | 48.54 | 1.64 | 0.96 | 1.60 | 11.97 |
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Ryan Gorenstein J.D. | Pres, CEO & Chairman | 1987 |
| Ms. Shannon Buggy | Sr. VP & Global Head of People | 1970 |
| Ms. Anna Shlimak | Sr. VP of Corp. Affairs & Strategy | 1986 |
| Mr. James Holm | Chief Financial Officer | NA |
| Mr. Carlos Cortez | VP, Controller & Principal Accounting Officer | 1973 |
| Mr. Shayne J. Laidlaw | Director of Investor Relations & Strategy | NA |
| Mr. Terry Gregory-Joseph Doucet | Sr. VP of Legal & Regulatory Affairs and Corp. Sec. | 1990 |
| Mr. Jeffrey David Jacobson | Chief Growth Officer | 1986 |
| Mr. Arye Weigensberg | Head of R&D | NA |
| Mr. Kevin B Gifford | VP of Fin. | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.